RUNX1T1 and acute myeloid leukemia: Avapritinib 100 mg daily was started a and bone marrow biopsy 30 days later revealed CR without measurable residual disease by flow, PCR for AML-ETO and NGS for KIT. This favorable response allowed a second alloHSCT 112 days after achieving CR from a 9/10 HLA mismatched unrelated donor after fludarabine and melphalan with post-transplant cyclophosphamide.